What do systematic reviews say?

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 191 participants
  Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 138 participants
  Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 136 participants
  Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 187 participants
  Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 127 participants
  Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 123 participants
  Moderate

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 234 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 612 participants
  Very low

DFX film‐coated tablet vs DFX dispersible tablet

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 91 participants
  Very low

DFX film‐coated tablet vs DFX dispersible tablet

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 54 participants
  Very low

DFP and DFO vs DFP

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 369 participants
  Low

DFP and DFO vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 281 participants
  Low

DFP and DFO vs DFP and DFX

Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… may leads to lower adherence to iron chelation therapy rates (n, N) compared with DFP plus deferasirox (DFX) (low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.84 [0.72, 0.99]
  1 study · 96 participants
  Low

Deferasirox vs deferiprone (DFO)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 452 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 390 participants
  Low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes total reported SAEs (from therapy, disease, non‐adherence) compared with deferoxamine (DFO) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 1.43 [0.83, 2.46]
  1 study · 228 participants
  Very low

Medication management vs usual care

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Deferasirox vs deferiprone (DFO)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Deferasirox vs deferiprone (DFO)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  1.54 [0.44, 5.39]
  1 study · 390 participants
  Very low